Table 2. Comparison of clinical and electrodiagnostic outcomes within and between groups.
| Outcome | PMS group | Control group | Between group differencea | p-valueb | ||
|---|---|---|---|---|---|---|
| Mean (SD) | p-valuec | Mean (SD) | p-valuec | Coefficient (95% CI) | ||
| Th-BQ: SSS | ||||||
| - Pretreatment | 2.3 (0.7) | 2.1 (0.7) | ||||
| - 2 Weeks | 1.6 (0.3) | 0.009 | 1.8 (0.4) | 0.15 | −0.17 [−0.49 to −0.14] | 0.27 |
| Th-BQ: FSS | ||||||
| - Pretreatment | 1.8 (0.4) | 1.6 (0.7) | ||||
| - 2 Weeks | 1.5 (0.5) | 0.15 | 1.7 (0.6) | 0.80 | −0.26 [−0.67 to 0.16] | 0.22 |
| Pinch strength (lbs) | ||||||
| - Pretreatment | 10.6 (2.6) | 14.6 (4.2) | ||||
| - 2 Weeks | 13.8 (3.0) | <0.001 | 15.9 (5.2) | 0.11 | 1.91 [−0.33 to 4.14] | 0.09 |
| Peak DSL (ms) | ||||||
| - Pretreatment | 5.1 (1.1) | 5.3 (2.7) | ||||
| - 2 Weeks | 5.0 (1.1) | 0.49 | 5.3 (2.7) | 0.82 | −0.05 [−0.22 to 0.32] | 0.71 |
| SNAP amplitude (µV) | ||||||
| - Pretreatment | 8.7 (4.2) | 11.7 (6.2) | ||||
| - 2 Weeks | 14.3 (5.2) | 0.002 | 15.4 (8.3) | 0.12 | 1.06 [−4.47 to −6.59] | 0.69 |
| Onset DML (ms) | ||||||
| - Pretreatment | 4.9 (0.9) | 4.6 (1.2) | ||||
| - 2 Weeks | 4.9 (1.1) | 0.12 | 4.7 (1.1) | 0.35 | −0.04 [−0.33 to −0.25] | 0.78 |
| CMAP amplitude (mV) | ||||||
| - Pre-treatment | 9.2 (2.4) | 8.4 (2.8) | ||||
| - 2 Weeks | 8.3 (1.7) | 0.13 | 8.0 (2.7) | 0.35 | −0.12 [−1.44 to −1.18] | 0.84 |
Note:
aCoefficient, corresponding 95% CI and p-valueb derived from multiple linear regression model. p-valuec derived from paired t-test (within-group comparison).